Latest news with #PLANO
Associated Press
19-05-2025
- Business
- Associated Press
AnX Robotica Unveils NaviCam XS, NaviCam XST, and ESView 3.0 at DDW 2025 to Exceptional Industry Response
PLANO, Texas, May 19, 2025 /PRNewswire/ -- AnX Robotica, a leader in robotic capsule endoscopy and advanced GI diagnostics, proudly announced the successful launch of NaviCam XS, NaviCam XST, and ESView 3.0 during Digestive Disease Week (DDW) 2025. The unveiling drew exceptional interest, with clinicians, researchers, and industry professionals visiting the AnX Robotica booth to witness the next evolution in GI visualization technology. NaviCam XS, the latest addition to the NaviCam platform, introduces a capsule that is 44% smaller by volume than standard small bowel capsules, designed for enhanced patient comfort and easier ingestion without compromising on image quality or diagnostic reliability. This next-generation capsule further advances the possibilities of capsule endoscopy. Alongside NaviCam XS, NaviCam XST made its debut, offering real-time esophageal visualization through a tethered capsule design. With ESView RT Display, clinicians can seamlessly navigate the esophagus without the need for sedation, providing an ideal solution for evaluating conditions such as reflux, and esophageal varices in real-time. AnX Robotica also showcased ESView 3.0, the most advanced version of its software platform to date. With an intuitive interface, enhanced image clarity, and streamlined workflow, ESView 3.0 allows for faster interpretation, real-time annotation, and seamless report generation—enabling physicians to optimize diagnostic efficiency and patient outcomes. 'The response at DDW 2025 has been overwhelmingly positive,' said Stu Wildhorn, Vice President of Marketing and Product Management at AnX Robotica. 'The enthusiasm from clinicians around NaviCam XS, XST, and ESView 3.0 underscores the market's demand for non-invasive, high-resolution GI visualization. These innovations are not just advancing technology; they are setting a new standard for patient care.' The high-traffic booth at DDW served as a launchpad for these technologies, with live demonstrations, hands-on sessions, and presentations that highlighted the precision, ease of use, and clinical impact of the new products. Attendees expressed strong interest in how these solutions can redefine both diagnostic efficiency and patient experience. AnX Robotica remains committed to pushing the boundaries of capsule endoscopy and GI diagnostics, adding to its growing portfolio, which includes NaviCam SB with ProScan™, MotiliCap, NaviCam Colon*, IntraMarX, and VibraBot. *Colon Capsule is not available in the United States View original content to download multimedia: SOURCE AnX Robotica
Yahoo
19-05-2025
- Business
- Yahoo
AnX Robotica Unveils NaviCam XS, NaviCam XST, and ESView 3.0 at DDW 2025 to Exceptional Industry Response
PLANO, Texas, May 19, 2025 /PRNewswire/ -- AnX Robotica, a leader in robotic capsule endoscopy and advanced GI diagnostics, proudly announced the successful launch of NaviCam XS, NaviCam XST, and ESView 3.0 during Digestive Disease Week (DDW) 2025. The unveiling drew exceptional interest, with clinicians, researchers, and industry professionals visiting the AnX Robotica booth to witness the next evolution in GI visualization technology. NaviCam XS, the latest addition to the NaviCam platform, introduces a capsule that is 44% smaller by volume than standard small bowel capsules, designed for enhanced patient comfort and easier ingestion without compromising on image quality or diagnostic reliability. This next-generation capsule further advances the possibilities of capsule endoscopy. Alongside NaviCam XS, NaviCam XST made its debut, offering real-time esophageal visualization through a tethered capsule design. With ESView RT Display, clinicians can seamlessly navigate the esophagus without the need for sedation, providing an ideal solution for evaluating conditions such as reflux, and esophageal varices in real-time. AnX Robotica also showcased ESView 3.0, the most advanced version of its software platform to date. With an intuitive interface, enhanced image clarity, and streamlined workflow, ESView 3.0 allows for faster interpretation, real-time annotation, and seamless report generation—enabling physicians to optimize diagnostic efficiency and patient outcomes. "The response at DDW 2025 has been overwhelmingly positive," said Stu Wildhorn, Vice President of Marketing and Product Management at AnX Robotica. "The enthusiasm from clinicians around NaviCam XS, XST, and ESView 3.0 underscores the market's demand for non-invasive, high-resolution GI visualization. These innovations are not just advancing technology; they are setting a new standard for patient care." The high-traffic booth at DDW served as a launchpad for these technologies, with live demonstrations, hands-on sessions, and presentations that highlighted the precision, ease of use, and clinical impact of the new products. Attendees expressed strong interest in how these solutions can redefine both diagnostic efficiency and patient experience. AnX Robotica remains committed to pushing the boundaries of capsule endoscopy and GI diagnostics, adding to its growing portfolio, which includes NaviCam SB with ProScan™, MotiliCap, NaviCam Colon*, IntraMarX, and VibraBot. *Colon Capsule is not available in the United States View original content to download multimedia: SOURCE AnX Robotica
Yahoo
19-05-2025
- Business
- Yahoo
AnX Robotica Unveils NaviCam XS, NaviCam XST, and ESView 3.0 at DDW 2025 to Exceptional Industry Response
PLANO, Texas, May 19, 2025 /PRNewswire/ -- AnX Robotica, a leader in robotic capsule endoscopy and advanced GI diagnostics, proudly announced the successful launch of NaviCam XS, NaviCam XST, and ESView 3.0 during Digestive Disease Week (DDW) 2025. The unveiling drew exceptional interest, with clinicians, researchers, and industry professionals visiting the AnX Robotica booth to witness the next evolution in GI visualization technology. NaviCam XS, the latest addition to the NaviCam platform, introduces a capsule that is 44% smaller by volume than standard small bowel capsules, designed for enhanced patient comfort and easier ingestion without compromising on image quality or diagnostic reliability. This next-generation capsule further advances the possibilities of capsule endoscopy. Alongside NaviCam XS, NaviCam XST made its debut, offering real-time esophageal visualization through a tethered capsule design. With ESView RT Display, clinicians can seamlessly navigate the esophagus without the need for sedation, providing an ideal solution for evaluating conditions such as reflux, and esophageal varices in real-time. AnX Robotica also showcased ESView 3.0, the most advanced version of its software platform to date. With an intuitive interface, enhanced image clarity, and streamlined workflow, ESView 3.0 allows for faster interpretation, real-time annotation, and seamless report generation—enabling physicians to optimize diagnostic efficiency and patient outcomes. "The response at DDW 2025 has been overwhelmingly positive," said Stu Wildhorn, Vice President of Marketing and Product Management at AnX Robotica. "The enthusiasm from clinicians around NaviCam XS, XST, and ESView 3.0 underscores the market's demand for non-invasive, high-resolution GI visualization. These innovations are not just advancing technology; they are setting a new standard for patient care." The high-traffic booth at DDW served as a launchpad for these technologies, with live demonstrations, hands-on sessions, and presentations that highlighted the precision, ease of use, and clinical impact of the new products. Attendees expressed strong interest in how these solutions can redefine both diagnostic efficiency and patient experience. AnX Robotica remains committed to pushing the boundaries of capsule endoscopy and GI diagnostics, adding to its growing portfolio, which includes NaviCam SB with ProScan™, MotiliCap, NaviCam Colon*, IntraMarX, and VibraBot. *Colon Capsule is not available in the United States View original content to download multimedia: SOURCE AnX Robotica
Associated Press
13-05-2025
- Business
- Associated Press
Lock Volume Rises 3.2% in April, Driven by Uptick in FHA Loans, Despite Economic Volatility
- Optimal Blue's April 2025 Market Advantage data report shows stronger purchase activity, a shifting loan mix, and signs of investor caution - PLANO, Texas, May 13, 2025 (SEND2PRESS NEWSWIRE) — Optimal Blue today released its April 2025 Market Advantage mortgage data report showing total loan lock volume rose 3.2% month-over-month (MoM) as the spring homebuying season progressed, with purchase locks up 7.5% despite ongoing economic pressures. April kicked off with significant volatility in the bond market as investors responded to tariff announcements. Over the first 10 days of the month, interest rates fluctuated between 6.48% and 6.98%, a 50-basis-point (bps) range. The benchmark OBMMI 30-year conforming fixed rate briefly fell below 6.5% for the first time since October 2024 before climbing to end the month at 6.7%, about 10 bps above where it started. 'Last month's report showed early signs of spring homebuyer activity, and April confirms the season is underway with a solid increase in purchase locks,' said Brennan O'Connell, director of data solutions at Optimal Blue. 'We also saw a shift toward FHA loans, often used by first-time or credit-challenged buyers, and away from non-conforming products, possibly reflecting investor caution in response to broader economic uncertainty.' Key findings from the Market Advantage report, derived from direct-source mortgage lock data, include: The full Market Advantage report, which provides more detailed findings and additional insights into U.S. mortgage market trends, can be viewed at (PDF): This month's Market Advantage podcast features Optimal Blue Chief Product Officer Erin Wester, discussing the impact of technological innovations in the mortgage industry. Watch or listen to the episode: About the Market Advantage Report Optimal Blue issues the Market Advantage mortgage data report each month to provide early insight into U.S. mortgage trends. Leveraging lender rate lock data from the Optimal Blue PPE – the mortgage industry's most widely used product, pricing, and eligibility engine – the Market Advantage provides a view of early-stage origination activity. Unlike self-reported survey data, mortgage lock data is direct-source data that accurately reflects the in-process loans in lenders' pipelines. Nothing herein shall be construed as, nor is Optimal Blue providing, any legal, trading, hedging, or financial advice. About Optimal Blue Optimal Blue effectively bridges the primary and secondary mortgage markets to deliver the industry's only end-to-end capital markets platform. The company helps lenders of all sizes and scopes maximize profitability and operate efficiently so they can help American borrowers achieve the dream of homeownership. Through innovative technology, a network of interconnectivity, rich data insights, and expertise gathered over more than 20 years, Optimal Blue is an experienced partner that, in any market environment, allows lenders to optimize their advantage from pricing accuracy to margin protection, and every step in between. To learn more, visit MULTIMEDIA: Image link for media: Image caption: Optimal Blue's April 2025 Market Advantage mortgage data report. NEWS SOURCE: Optimal Blue ### MEDIA ONLY CONTACT: (not for publication online or in print) Leslie W. Colley Depth for Optimal Blue [email protected] (678) 622-6229 ### Keywords: Mortgage, Optimal Blue, Market Advantage mortgage data report, FHA Loans, housing market, PLANO, Texas This press release was issued on behalf of the news source (Optimal Blue) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P126135 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Yahoo
21-03-2025
- Business
- Yahoo
European Wax Center, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLANO, Texas, March 21, 2025 (GLOBE NEWSWIRE) -- European Wax Center, Inc. (NASDAQ: EWCZ) (the 'Company' or 'European Wax Center'), the leading franchisor and operator of out-of-home waxing services in the United States, announced that on March 21, 2025, and in connection with the previously announced appointment of Katie Mullen as the Company's Chief Commercial Officer, the Company's Board of Directors approved grants of (i) restricted stock units ('RSUs') covering 160,000 shares of the Company's Class A common stock (the 'Mullen RSUs'), (ii) non-qualified stock option awards to purchase 220,000 shares of the Company's Class A common stock with an exercise price of $3.99, which is equal to the closing price of the Company's Class A common stock on the Nasdaq Stock Market on March 21, 2025, (iii) non-qualified stock option awards to purchase 180,000 shares of the Company's Class A common stock with an exercise price of $9.00, and (iv) non-qualified stock option awards to purchase 180,000 shares of the Company's Class A common stock with an exercise price of $12.00 ((ii), (iii) and (iv) collectively, the 'Mullen Options'). The Mullen RSUs and Mullen Options were granted pursuant to the Company's 2025 Inducement Plan. The Mullen RSUs will vest in equal installments on each of the first four anniversaries of January 28, 2025, and the Mullen Options will vest in full on the fourth anniversary of January 28, 2025, in each case subject to Ms. Mullen's continued employment with the Company on each such date. The Mullen RSUs and Mullen Options are subject to the terms and conditions of the Company's 2025 Inducement Plan and the terms and conditions of the RSU award agreement and stock option award agreement covering the applicable grant. The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company (or following a bona fide period of non-employment), as an inducement material to such individuals' entering into employment with the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Mullen RSUs and Mullen Options were granted as such inducement material to Ms. Mullen entering into employment with the Company. About European Wax Center, Inc. European Wax Center, Inc. (NASDAQ: EWCZ) is the leading franchisor and operator of out-of-home waxing services in the United States. European Wax Center locations perform more than 23 million services per year, providing guests with an unparalleled, professional personal care experience administered by highly trained wax specialists within the privacy of clean, individual waxing suites. The Company continues to revolutionize the waxing industry with its innovative Comfort Wax® formulated with the highest quality ingredients to make waxing a more efficient and relatively painless experience, along with its collection of proprietary products to help enhance and extend waxing results. By leading with its values – We Care About Each Other, We Do the Right Thing, We Delight Our Guests, and We Have Fun While Being Awesome – the Company is proud to be Certified™ by Great Place to Work®. European Wax Center, Inc. was founded in 2004 and is headquartered in Plano, Texas. Its network, which includes more than 1,000 centers in 45 states, generated sales of $951 million in fiscal 2024. For more information, including how to receive your first wax free, please visit: Investor ContactEuropean Wax Center, Media ContactEdelman SmithfieldJosh Hochberg & Ashna VasaEWCIR@ Zeno GroupSophia
